These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

215 related items for PubMed ID: 15019272

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. 8-Methoxyquinolines as PDE4 inhibitors.
    Billah M, Buckley GM, Cooper N, Dyke HJ, Egan R, Ganguly A, Gowers L, Haughan AF, Kendall HJ, Lowe C, Minnicozzi M, Montana JG, Oxford J, Peake JC, Picken CL, Piwinski JJ, Naylor R, Sabin V, Shih NY, Warneck JB.
    Bioorg Med Chem Lett; 2002 Jun 17; 12(12):1617-9. PubMed ID: 12039575
    [Abstract] [Full Text] [Related]

  • 24. Inhibitory effects of flavonoids on phosphodiesterase isozymes from guinea pig and their structure-activity relationships.
    Ko WC, Shih CM, Lai YH, Chen JH, Huang HL.
    Biochem Pharmacol; 2004 Nov 15; 68(10):2087-94. PubMed ID: 15476679
    [Abstract] [Full Text] [Related]

  • 25. Prostaglandin E2-mediated anabolic effect of a novel inhibitor of phosphodiesterase 4, XT-611, in the in vitro bone marrow culture.
    Miyamoto K, Suzuki H, Yamamoto S, Saitoh Y, Ochiai E, Moritani S, Yokogawa K, Waki Y, Kasugai S, Sawanishi H, Yamagami H.
    J Bone Miner Res; 2003 Aug 15; 18(8):1471-7. PubMed ID: 12929936
    [Abstract] [Full Text] [Related]

  • 26. Differential type 4 cAMP-specific phosphodiesterase (PDE4) expression and functional sensitivity to PDE4 inhibitors among rats, monkeys and humans.
    Bian H, Zhang J, Wu P, Varty LA, Jia Y, Mayhood T, Hey JA, Wang P.
    Biochem Pharmacol; 2004 Dec 01; 68(11):2229-36. PubMed ID: 15498513
    [Abstract] [Full Text] [Related]

  • 27. The potential of PDE4 inhibitors in asthma or COPD.
    Spina D.
    Curr Opin Investig Drugs; 2000 Oct 01; 1(2):204-13. PubMed ID: 11249575
    [Abstract] [Full Text] [Related]

  • 28. Phosphodiesterase 9: insights from protein structure and role in therapeutics.
    Singh N, Patra S.
    Life Sci; 2014 Jun 13; 106(1-2):1-11. PubMed ID: 24746902
    [Abstract] [Full Text] [Related]

  • 29. Phosphodiesterase inhibitors as antiplatelet agents in vascular surgery.
    Kambayashi J, Watase M, Kawasaki T, Shiba E, Sakon M, Mori T, Isaka Y, Kimura K, Kamada T.
    Adv Second Messenger Phosphoprotein Res; 1992 Jun 13; 25():383-93. PubMed ID: 1313269
    [No Abstract] [Full Text] [Related]

  • 30. Synthesis and profile of SCH351591, a novel PDE4 inhibitor.
    Billah M, Cooper N, Cuss F, Davenport RJ, Dyke HJ, Egan R, Ganguly A, Gowers L, Hannah DR, Haughan AF, Kendall HJ, Lowe C, Minnicozzi M, Montana JG, Naylor R, Oxford J, Peake JC, Piwinski JJ, Runcie KA, Sabin V, Sharpe A, Shih NY, Warneck JB.
    Bioorg Med Chem Lett; 2002 Jun 17; 12(12):1621-3. PubMed ID: 12039576
    [Abstract] [Full Text] [Related]

  • 31. PDE4 inhibitors: new xanthine analogues.
    Montana JG, Cooper N, Dyke HJ, Gowers L, Gregory JP, Hellewell PG, Miotla J, Morris K, Naylor R, Tuladhar B, Warneck JB.
    Bioorg Med Chem Lett; 1998 Oct 20; 8(20):2925-30. PubMed ID: 9873649
    [Abstract] [Full Text] [Related]

  • 32. 2-Substituted-4-methoxybenzimidazole-based PDE4 inhibitors.
    Regan J, Bruno J, McGarry D, Poli G, Hanney B, Bower S, Travis J, Sweeney D, Miller B, Souness J, Djuric S.
    Bioorg Med Chem Lett; 1998 Oct 06; 8(19):2737-42. PubMed ID: 9873613
    [Abstract] [Full Text] [Related]

  • 33. Keynote review: phosphodiesterase-4 as a therapeutic target.
    Houslay MD, Schafer P, Zhang KY.
    Drug Discov Today; 2005 Nov 15; 10(22):1503-19. PubMed ID: 16257373
    [Abstract] [Full Text] [Related]

  • 34. The long and short of vascular smooth muscle phosphodiesterase-4 as a putative therapeutic target.
    Houslay MD.
    Mol Pharmacol; 2005 Sep 15; 68(3):563-7. PubMed ID: 15958394
    [Abstract] [Full Text] [Related]

  • 35. CoMFA and CoMSIA 3D-quantitative structure-activity relationship model on benzodiazepine derivatives, inhibitors of phosphodiesterase IV.
    Ducrot P, Andrianjara CR, Wrigglesworth R.
    J Comput Aided Mol Des; 2001 Sep 15; 15(9):767-85. PubMed ID: 11776290
    [Abstract] [Full Text] [Related]

  • 36. Selective phosphodiesterase (PDE)-4 inhibitors: a novel approach to treating memory deficit?
    Ghavami A, Hirst WD, Novak TJ.
    Drugs R D; 2006 Sep 15; 7(2):63-71. PubMed ID: 16542053
    [Abstract] [Full Text] [Related]

  • 37. Selective inhibitors of calmodulin-dependent phosphodiesterase and other enzymes.
    Hidaka H, Inagaki M, Nishikawa M, Tanaka T.
    Methods Enzymol; 1988 Sep 15; 159():652-60. PubMed ID: 2842626
    [No Abstract] [Full Text] [Related]

  • 38. Effects of imipramine, nomifensine and d-amphetamine on type B monoamine oxidase, cyclic AMP phosphodiesterase and dopamine-beta-hydroxylase.
    Izumi H, Togashi O, Hayakari M, Hayashi S, Ozawa H.
    Tohoku J Exp Med; 1976 Mar 15; 118(3):223-31. PubMed ID: 178070
    [Abstract] [Full Text] [Related]

  • 39. Inhibitors of cyclic nucleotide phosphodiesterase PDE3 as adjunct therapy for dilated cardiomyopathy.
    Movsesian MA, Alharethi R.
    Expert Opin Investig Drugs; 2002 Nov 15; 11(11):1529-36. PubMed ID: 12437500
    [Abstract] [Full Text] [Related]

  • 40. Cyclic AMP-specific phosphodiesterase-4 as a target for the development of antidepressant drugs.
    Zhang HT.
    Curr Pharm Des; 2009 Nov 15; 15(14):1688-98. PubMed ID: 19442182
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.